Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 8/20 | 0.38 |
| ▸ | THRA | P10827 | 7/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | GCG | P01275 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131338 | 0.89 | ADORA2A (0.41) | ESR2MIFGCGTP53ALDH1A1 | |
| SCHEMBL3136298 | 0.87 | THRA (0.51) | ESR2MIFTHRBTHRANAMPT | |
| SCHEMBL3142310 | 0.85 | THRB (0.53) | ESR2MIFTHRBTHRA | |
| SCHEMBL3133547 | 0.83 | THRA (0.44) | ESR2THRBTHRAHDAC1HDAC2 | |
| SCHEMBL3129968 | 0.81 | ESR2 (0.43) | ESR2MIFTHRBTHRA | |
| SCHEMBL3133562 | 0.80 | ESR2 (0.49) | ESR2MIFALDH1A1MAPT | |
| SCHEMBL3137618 | 0.79 | ESR2 (0.43) | ESR2THRBTHRAGCGHDAC1 | |
| SCHEMBL3129766 | 0.79 | P2RX7 (0.40) | THRBTHRAMAPT | |
| SCHEMBL5072179 | 0.77 | ESR2 (0.49) | ESR2MIFALDH1A1MAPT | |
| SCHEMBL3146020 | 0.77 | MAPT (0.54) | ESR2HDAC1HDAC2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | ESR2 270/4885MIF 4307/4885THRB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.